There’s a chance for investors in pharmaceuticals that is been “underrepresented for a really very long time,” in line with fund manager Philip Ripman of Storebrand Asset Management. The realm is women’s healthcare, in line with Ripman, who manages the $1 billion Storebrand Global Solutions fund. “Inside the portfolio, the aspect that we have really focused in on is female health care. It’s one among the areas that has been each under-researched and underrepresented for a really very long time,” he told Pro Talks last week. In accordance with a Mckinsey report last yr , beyond breast cancer, female health conditions attracted just 1% of pharmaceutical research funding in 2020. In medical tech funding, only 2% was focused on non-cancer-related women’s health conditions. Many studies had been done “from a person’s perspective,” said Ripman, adding that that is now changing. “I feel numerous the brand new business models coming through on this sense are interesting,” he said. “What we would like to see is more deal with the feminine healthcare side throughout the portfolio.” The realm of femtech — or software and tech products referring to women’s health — is definitely growing. In 2021, enterprise capital investment in femtech surpassed $2 billion for the primary time, in line with Pitchbook, which expects it to achieve $3 billion by 2030. Stocks to think about Inside Ripman’s fund, which has a deal with sustainability, there are quite a lot of stocks that play into this theme. They include Hologic , a U.S.-based medtech company with a deal with women’s health, American medtech firm Becton Dickinson , and Europe-based pharmaceutical firm Gedeon Richter, which has women’s healthcare as one among its areas of experience. In accordance with FactSet data, analysts give Hologic average potential upside of 14%, although only 35% of those covering it have a buy rating on the stock. Becton Dickinson also received around 14% potential upside from analysts, and 65% of them give it a buy rating. The Storebrand Global Solutions fund invests across 4 themes : smart cities, circular economy, equal opportunities and renewable energy. The fund’s principle is to avoid firms that make over 5% of their revenues from fossil fuels, tobacco, alcohol, war and other vice-related activities. The strategy appears to have paid off over the long run: it ranks top for 10-year annualized returns (15%) on Morningstar’s list of worldwide mega-cap equity funds.
A key step forward for Novo Nordisk’s GLP-1 pill
Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little...
